-- Grand Pharmaceutical Group (HKG:0512) said a liver cancer treatment developed by its Sirtex Medical associate reached the clinical endpoint of a U.S. clinical study, according to a Hong Kong bourse filing Monday.
Shares of the pharma firm gained nearly 3% in morning trade Tuesday.
Results from the DOORwaY90 clinical trial demonstrated that SIR-Spheres Y-90, a radiotherapy product for liver cancer, achieved a 90% complete response and a best overall response rate of 99% in subjects.
The treatment was previously approved by the U.S. Food and Drug Administration for the treatment of inoperable liver cancer based on interim data from the DOORwaY90 trial. It was also approved in China for unresectable colorectal cancer liver metastases.
Grand Pharmaceutical said the relevant clinical data will now provide "strong support" for the treatment's expansion of indications in China.